Theravance Biopharma Inc (TBPH)

$9.57

-0.11

(-1.14%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $9.51
    $9.75
    $9.57
    downward going graph

    0.63%

    Downside

    Day's Volatility :2.41%

    Upside

    1.8%

    downward going graph
  • $8.13
    $11.71
    $9.57
    downward going graph

    15.05%

    Downside

    52 Weeks Volatility :30.57%

    Upside

    18.27%

    downward going graph

Returns

PeriodTheravance Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
1.16%
6.4%
0.0%
6 Months
-0.93%
6.0%
0.0%
1 Year
-0.73%
8.5%
0.0%
3 Years
-31.0%
14.6%
-20.8%

Highlights

Market Capitalization
470.0M
Book Value
$4.22
Earnings Per Share (EPS)
-0.89
PEG Ratio
-0.05
Wall Street Target Price
15.4
Profit Margin
-72.78%
Operating Margin TTM
-77.27%
Return On Assets TTM
-5.66%
Return On Equity TTM
-15.56%
Revenue TTM
61.5M
Revenue Per Share TTM
1.19
Quarterly Revenue Growth YOY
39.2%
Gross Profit TTM
-12.0M
EBITDA
-41.7M
Diluted Eps TTM
-0.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.65
EPS Estimate Next Year
0.13
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.21

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Theravance Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 60.92%

Current $9.57
Target $15.40

Company Financials

FY18Y/Y Change
Revenue
60.4M
↑ 292.37%
Net Income
-215.5M
↓ 24.48%
Net Profit Margin
-357.01%
↑ 1497.96%
FY19Y/Y Change
Revenue
73.4M
↑ 21.61%
Net Income
-236.5M
↑ 9.71%
Net Profit Margin
-322.08%
↑ 34.93%
FY20Y/Y Change
Revenue
71.9M
↓ 2.12%
Net Income
-278.0M
↑ 17.58%
Net Profit Margin
-386.9%
↓ 64.82%
FY21Y/Y Change
Revenue
55.3M
↓ 23.03%
Net Income
-199.4M
↓ 28.27%
Net Profit Margin
-360.55%
↑ 26.35%
FY22Y/Y Change
Revenue
51.3M
↓ 7.17%
Net Income
-92.8M
↓ 53.45%
Net Profit Margin
-180.78%
↑ 179.77%
FY23Y/Y Change
Revenue
57.4M
↑ 11.84%
Net Income
-55.2M
↓ 40.54%
Net Profit Margin
-96.11%
↑ 84.67%
Q4 FY22Q/Q Change
Revenue
14.6M
↑ 17.65%
Net Income
-14.3M
↓ 101.56%
Net Profit Margin
-97.33%
↓ 7459.24%
Q1 FY23Q/Q Change
Revenue
10.4M
↓ 28.89%
Net Income
-22.1M
↑ 54.92%
Net Profit Margin
-212.04%
↓ 114.71%
Q2 FY23Q/Q Change
Revenue
13.7M
↑ 31.99%
Net Income
-15.6M
↓ 29.17%
Net Profit Margin
-113.79%
↑ 98.25%
Q3 FY23Q/Q Change
Revenue
15.7M
↑ 14.14%
Net Income
-9.0M
↓ 42.79%
Net Profit Margin
-57.03%
↑ 56.76%
Q4 FY23Q/Q Change
Revenue
17.6M
↑ 11.93%
Net Income
-8.5M
↓ 4.91%
Net Profit Margin
-48.45%
↑ 8.58%
Q1 FY24Q/Q Change
Revenue
14.5M
↓ 17.43%
Net Income
-11.7M
↑ 37.05%
Net Profit Margin
-80.42%
↓ 31.97%
FY18Y/Y Change
Total Assets
560.2M
↑ 26.92%
Total Liabilities
611.8M
↑ 87.55%
FY19Y/Y Change
Total Assets
408.8M
↓ 27.03%
Total Liabilities
632.7M
↑ 3.41%
FY20Y/Y Change
Total Assets
469.1M
↑ 14.73%
Total Liabilities
772.8M
↑ 22.15%
FY21Y/Y Change
Total Assets
374.8M
↓ 20.09%
Total Liabilities
713.4M
↓ 7.69%
FY22Y/Y Change
Total Assets
607.4M
↑ 62.05%
Total Liabilities
165.6M
↓ 76.79%
FY23Y/Y Change
Total Assets
382.0M
↓ 37.11%
Total Liabilities
169.0M
↑ 2.06%
Q4 FY22Q/Q Change
Total Assets
607.4M
↓ 20.44%
Total Liabilities
165.6M
↓ 41.47%
Q1 FY23Q/Q Change
Total Assets
538.6M
↓ 11.34%
Total Liabilities
168.0M
↑ 1.44%
Q2 FY23Q/Q Change
Total Assets
446.6M
↓ 17.07%
Total Liabilities
166.5M
↓ 0.91%
Q3 FY23Q/Q Change
Total Assets
413.6M
↓ 7.4%
Total Liabilities
167.5M
↑ 0.6%
Q4 FY23Q/Q Change
Total Assets
382.0M
↓ 7.64%
Total Liabilities
169.0M
↑ 0.92%
Q1 FY24Q/Q Change
Total Assets
371.3M
↓ 2.8%
Total Liabilities
166.4M
↓ 1.52%
FY18Y/Y Change
Operating Cash Flow
-112.9M
↓ 43.86%
Investing Cash Flow
176.7M
↓ 413.68%
Financing Cash Flow
225.2M
↑ 13499.03%
FY19Y/Y Change
Operating Cash Flow
-238.2M
↑ 111.04%
Investing Cash Flow
-83.1M
↓ 147.0%
Financing Cash Flow
1.3M
↓ 99.43%
FY20Y/Y Change
Operating Cash Flow
-250.4M
↑ 5.12%
Investing Cash Flow
10.7M
↓ 112.91%
Financing Cash Flow
263.1M
↑ 20278.39%
FY21Y/Y Change
Operating Cash Flow
-207.9M
↓ 16.99%
Investing Cash Flow
124.5M
↑ 1061.22%
Financing Cash Flow
91.9M
↓ 65.08%
FY22Y/Y Change
Operating Cash Flow
-187.0M
↓ 10.04%
Investing Cash Flow
1.2B
↑ 826.96%
Financing Cash Flow
-758.8M
↓ 926.05%
Q4 FY22Q/Q Change
Operating Cash Flow
-124.1M
↑ 460.4%
Investing Cash Flow
39.2M
↓ 96.36%
Financing Cash Flow
-35.5M
↓ 95.09%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.2M
↓ 90.95%
Investing Cash Flow
-43.0M
↓ 209.92%
Financing Cash Flow
-56.2M
↑ 58.55%
Q2 FY23Q/Q Change
Operating Cash Flow
-12.4M
↑ 10.83%
Investing Cash Flow
11.0M
↓ 125.66%
Financing Cash Flow
-80.7M
↑ 43.46%

Technicals Summary

Sell

Neutral

Buy

Theravance Biopharma Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Theravance Biopharma Inc
Theravance Biopharma Inc
9.37%
-0.93%
-0.73%
-31.0%
-47.13%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Theravance Biopharma Inc
Theravance Biopharma Inc
NA
NA
-0.05
-0.65
-0.16
-0.06
NA
4.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Theravance Biopharma Inc
Theravance Biopharma Inc
Buy
$470.0M
-47.13%
NA
-72.78%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Theravance Biopharma Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 17.56M → 14.50M (in $), with an average decrease of 17.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.51M → -11.66M (in $), with an average decrease of 37.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 59.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 196.2% return, outperforming this stock by 227.2%

Institutional Holdings

  • Weiss Asset Management LP

    15.33%
  • Madison Avenue Partners, LP

    14.42%
  • Baupost Group LLC

    13.56%
  • BlackRock Inc

    8.65%
  • Irenic Capital Management LP

    5.68%
  • Vanguard Group Inc

    5.52%

Company Information

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Organization
Theravance Biopharma Inc
Employees
99
CEO
Mr. Rick E. Winningham M.B.A.
Industry
Health Technology

FAQs